The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.